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Abstract
Background: Plasmodium vivax is responsible for the majority of malarial infection in the Indian subcontinent. This
species of the parasite is generally believed to cause a relatively benign form of the disease. However, recent
reports from different parts of the world indicate that vivax malaria can also have severe manifestation. Host
response to the parasite invasion is thought to be an important factor in determining the severity of manifestation.
In this paper, attempt was made to determine the host metabolic response associated with P. vivax infection by
means of NMR spectroscopy-based metabonomic techniques in an attempt to better understand the disease
pathology.
Methods: NMR spectroscopy of urine samples from P. vivax-infected patients, healthy individuals and non-malarial
fever patients were carried out followed by multivariate statistical analysis. Two data analysis techniques were
employed, namely, Principal Component Analysis [PCA] and Orthogonal Projection to Latent Structure Discriminant
Analysis [OPLS-DA]. Several NMR signals from the urinary metabolites were further selected for univariate
comparison among the classes.
Results: The urine metabolic profiles of P. vivax-infected patients were distinct from those of healthy individuals as well
as of non-malarial fever patients. A highly predictive model was constructed from urine profile of malarial and non-
malarial fever patients. Several metabolites were found to be varying significantly across these cohorts. Urinary ornithine
seems to have the potential to be used as biomarkers of vivax malaria. An increasing trend in pipecolic acid was also
observed. The results suggest impairment in the functioning of liver as well as impairment in urea cycle.
Conclusions: The results open up a possibility of non-invasive analysis and diagnosis of P. vivax using urine
metabolic profile. Distinct variations in certain metabolites were recorded, and amongst these, ornithine may have
the potential of being used as biomarker of malaria. Pipecolic acid also showed increasing trend in the malaria
patient compared to the other groups.
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Background
Malaria is caused by parasites of the genus Plasmodium.
The five Plasmodium species that are responsible for
human malaria are Plasmodium vivax, Plasmodium fal-
ciparum, Plasmodium malariae, Plasmodium ovale and
Plasmodium knowlesi [1]. Every year, 200-300 million
people are affected with malaria with an annual mortal-
ity rate of nearly one million [2]. Sub-Saharan Africa
a n dS o u t h e a s tA s i aa r es o m eo ft h em o s ta f f e c t e d
regions. In India, P. vivax is the predominant cause of
clinical malaria [3].
Metabonomics is a comparatively recently developed
technology defined as the global, dynamic response of
living organism towards genetic and environmental per-
turbations [4]. The technique involves the NMR or mass
* Correspondence: sharma@tifr.res.in; hms@tifr.res.in
1Department of Chemical Sciences, Tata Institute of Fundamental Research,
Homi Bhabha Road, Mumbai 400 005, India
2Department of Biological Sciences, Tata Institute of Fundamental Research,
Homi Bhabha Road, Mumbai 400 005, India
Full list of author information is available at the end of the article
Sengupta et al. Malaria Journal 2011, 10:384
http://www.malariajournal.com/content/10/1/384
© 2011 Sengupta et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.spectra analysis of biofluids such as urine and serum,
etc. followed by multivariate analyses using Principal
Component Analysis [PCA] or Orthogonal Partial Least
Square - Discriminant Analysis [OPLSDA]. Essentially
this provides the clustering of the samples into classes.
This also provides the identity of specific NMR/mass
spectral signature[s] that are responsible for the cluster-
ing/classification. This, in turn, leads to identification of
the metabolite[s] that are specifically perturbed in
response to the stress factor [genetic or environmental]
under investigation [5]. Metabonomics, although a rela-
tively new technology, is being used extensively in phar-
macological industry [6,7]. Metabonomic analysis is also
being utilized in identification of novel biomarkers and/
or metabolic characterization during different diseases,
such as diabetes [8] and congenital heart disease [9].
Malaria is an ancient infectious disease that has
afflicted humans since pre-historic times. Severity in the
clinical malarial disease occurs frequently, and has been
well documented for P. falciparum infections [10,11].
The severity or pathogenicity is likely to be due to meta-
bolic complications arising as a result of host parasite
interactions in which the pathogen may divert the host
nutrients, and/or release toxic metabolites. Metabolomic
analysis will allow a direct read out for such complica-
tions. Using axenic cultures, the changes in metabolomic
profiles have been documented for the intraerythrocytic
stages of P. falciparum [12-14]. However, there have
been very few studies on the effects on the metabolic
profile of the host during malarial infection. Although
body fluids such as urine and plasma are amenable to
such metabolomic analysis, very few reports exist of such
studies. Urine, as an easily available fluid, is also a very
good reporter of the overall metabolic status of the whole
organism. Systemic level analysis of host metabolic
response towards malaria is delineated only in two rodent
model studies. In one of the studies, existence of sexual
dimorphism was shown in the alterations of sera, urine
and brain metabolic profile in the rodent model of
malaria [15]. In another study Nicholson and co-workers
delineated the global metabolic response to Plasmodium
berghei infection [16]. No metabolomic information
exists so far for human patient samples. In particular,
very little is known for P. vivax patients, although it has
been observed recently that P. vivax can cause high levels
of pathological complications [17,18].
In this report, a NMR based metabonomic approach is
delinated to study the urine samples of P. vivax malaria
patients and try to correlate the changes observed in
them to the known and reported biochemical processes.
The paper describes a study of global host metabolic
responses towards P. vivax infection. The results ascer-
tain differences in metabolic response in the urinary
metabolic profile of the P. vivax infected persons with
respect to that of healthy individuals and also with the
patients of non-malarial fever. The differential metabo-
lites are delineated, raising the possibility of a non-inva-
sive diagnosis of malaria.
Methods
Ethical aspects
This study was approved by and carried out according
to the guidelines of the Local Institutional Ethics Com-
mittee. Informed consent was obtained prior to sample
collection.
Sample collection
Midstream urine samples (~10 ml) of malaria-infected
individuals were collected from local pathological
laboratories in sterile tubes containing a final concentra-
tion of 0.02% sodium azide. The inclusion criteria fol-
lowed to recruit the subjects in the study were as
follows- (1) Adult males (age ranging from 30 to 50
years), (2) Malaria cohort of those patients that tested
positive for P. vivax by blood smear microscopy and (3)
Subjects able to consent through informed consent
document. Certain exclusion criteria were also followed
viz. (1) All females and males < 30 and > 50 years of
age, (2) Patients with P. falciparum and mixed P. falci-
parum/P. vivax infections and (3) Patients with other
chronic diseases and/or previous history of any type of
malarial infection. In total 53 individuals (all males)
were recruited for the study: 21 P. vivax-infected
patients, 21 healthy controls and 12 patients with non-
malarial fever. Their age ranges were: malaria patients:
35 ± 3.95 years: healthy individuals: 44 ± 3.18 years: and
non-malarial fever patients: 40.5 ± 5.33 years (median ±
standard error). The samples were transported from the
site of collection to the laboratory at 0°C and were
immediately processed [19].
Sample preparation for NMR experiments
An aliquot (800 μL) of collected urine sample was
mixed with 400 μL phosphate buffer (an 81:19 (v/v)
mixture of 0.2 M Na2HPO4 and 0.2 M NaH2PO4;p H
7.4, made in deionized and 0.22 mm filtered water).
This mixture was homogenized and left to stand for 5
min at ambient temperature following which it was cen-
trifuged for 6 min at 6000 g to remove any suspended
matter. The clear supernatant (600 μL) was transferred
to 5 mm NMR tube (Wilmad, USA) and 50 μLD 2O,
containing 2, 2-dimethyl-2-silapentane-5-sulfonic acid
(DSS) at 0.01% final concentration, was added to it. D2O
served as a field-frequency lock and DSS was the inter-
nal chemical shift reference. The samples were stored
frozen at -20°C until required for NMR experiments.
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The NMR spectra were acquired on AVANCE 500 MHz
Bruker NMR spectrometer equipped with a 5 mm
broad-band inverse probe. The operating frequency on
this machine was 500.13 MHz for
1H. For the 1D
experiments the spectral width was 12.01 ppm, an exci-
tation pulse of 9 μs (~70°), and a relaxation delay of 1 s
between consecutive pulses. This resulted in an acquisi-
tion time of 0.68 s and a cycle time of 1.68 s. A total of
64 transients were acquired into 8,192 data points. The
water suppression routine involved excitation sculpting
using gradients. For processing the FIDs were subjected
to exponential multiplication leading to an additional
line broadening of 0.20 Hz. A sine bell apodization was
also used prior to Fourier transformation. The
1HN M R
spectra were manually phase and baseline corrected. For
identification of metabolites two dimensional (2D)
experiments were performed on selected samples. 2D
COSY spectra were acquired with 32 transients in the
direct dimension for each of the 256 increments in the
indirect dimension. The spectral width was 12.01 in
both the dimensions. The pulse width used was 11.80 μs
with a delay of 1.5 s. The processing parameters of the
data included a QSINE window function, exponential
multiplication of 0.20 and 0.30 Hz in the direct and
indirect dimension respectively, followed by Fourier
transformation in both the dimensions. The 2D TOCSY
experiments were performed using similar acquisition
parameters. The processing parameters were also identi-
cal with an extra Gaussian multiplication of 0.10 Hz
prior to Fourier transformation in both the dimensions.
The 2D spectra aided in assignment of the NMR reso-
nances to the specific metabolites. In addition, compari-
son with reported experimental and calculated spectra
was done using Human Metabolome Data Base (http://
www.hmdb.ca/search/spectra).
Data reduction and analyses
The frequency domain
1H NMR spectra were manually
phased and baseline corrected. For data reduction the
individual spectrum (0.50 to 9.50 ppm) were divided
into frequency bins of width 0.04 ppm each resulting in
a total of 191 bins per spectrum. Each bin was inte-
grated using MestReC 4.7.0. In order to avoid the arte-
facts of water suppression and the variable
concentration of urea, the region 4.3 to 6.6 ppm was
excluded from the binning procedure. The integrals
were normalized to the total intensity of the spectrum
to compensate for the inter-sample dilution effects. This
was achieved by an algorithm developed in-house. The
data was mean-centered (the average value of each bin
for all samples was subtracted from individual integrals)
and Pareto scaled. The preceding operation resulted in
similar weight being given to all the bins and the
resultant multivariate models were not dominated by
bins representing metabolites high in concentration.
Next, the data so generated served as input for PCA and
OPLS-DA, which were performed on the SIMCA-P +
12.0 platform (Umetrics, Umea, Sweden).
PCA is an unsupervised pattern recognition technique
where no class identity is assigned to the samples a
priori. This helps in visualizing any pattern that is pre-
sent in the data and also identifies the outliers. The
class specific segregation can be refined using OPLS-
DA. This is a supervised technique where class specifi-
city is assigned towards the sample set ap r i o r i .T h i s
aided in the visualization of the data as scores plot. In
such a plot each point represents a spectrum and the
pattern and the segregation in the data can be visua-
lized. This pattern is due to one or more spectral bin(s)
which can be visualized using a loadings plot where
each point represents a spectral bin. The OPLS-DA
model is judged using two parameters. R
2X signifies the
total explained variation in the data whereas the Q
2
(cum) explains the extent of separation between the
classes as well as the predictability of the model.
Integration of NMR peaks
The spectral bins contributing to the variation seen in
the OPLS-DA models (visualized in terms of scores
plot) were assigned to specific metabolites as described
in the previous section. For further quantification of
these metabolites, univariate analysis of the NMR spec-
tral peaks was performed in the following way: the peak
of the metabolite contributing to the variation in the
OPLS-DA model was assigned in the one-dimensional
NMR spectral profiles of the individuals. These peaks
were integrated, normalized to the whole region of the
spectral profile and compared between the classes con-
cerned using student’s t-test to judge the significance in
their difference across the classes.
Results
Multivariate statistical analysis
1H NMR spectra of urine samples from patients and
healthy individuals were recorded followed by multivari-
ate statistical analyses. Representative
1HN M Rs p e c t r a
from individual belonging to the three groups are
shown in Figure 1 [I-III]. These samples were from indi-
viduals infected with P. vivax, patients with non-malarial
fever or healthy volunteers. For this analysis, only adult
male samples were used. The individuals with infection
had been referred to the pathology laboratories with
malaria-like clinical symptoms (chills, fever, splenome-
galy, etc.) and their infection status was confirmed by
standard peripheral blood smears.
The multivariate analysis was performed on two data
sets obtained from the
1H NMR spectra of urine samples.
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infected individuals and healthy controls. The second
data set consisted of patients with malaria and non-
malarial fever. Earlier data analysis by PCA of the
1H
NMR spectra of urine from the healthy individuals and P.
vivax-infected persons showed an inherent segregation
between the two classes [20]. The R
2Xv a l u ew a sf o u n d
to be 0.72 [20]. In the current study the OPLS-DA model
was built to visualize the class specific segregation and to
obtain the significant bins contributing to the variation
across the classes, i.e. P. vivax-infected patients and
healthy controls or non-malarial fever patients. The
OPLS-DA scores plot from the urinary NMR metabolic
profile of P. vivax-infected individuals and healthy con-
trols is shown in Figure 2. This model also showed segre-
gation of classes with R
2X = 0.41 and Q
2(cum) = 0.67.
However, the spread is typical of human samples since
there is enormous variation in genetic backgrounds as
well as food habits. This is to say, the samples under con-
sideration have factors other than malaria, which led to a
larger scatter among them. To ensure that the effect of
sex does not confound the analysis it was restricted to
male patients only. In spite of all these factors, the Q
2
(cum) was found to be significantly high, therefore it
implicated a considerable difference in the urinary meta-
bolic profile of malarial patients and healthy individuals.
OPLS-DA models made from NMR profile of urine sam-
ples of malaria patients and non malarial fever patients
showed Q
2(cum) = 0.89 and R
2X = 0.67. This indicates a
very good separation between the urinary profile of
malaria patients and non-malarial fever patients, which is
also evident from the PCA and OPLS-DA scores plot
shown in Figures 3 and 4 respectively. In order to identify
the spectral bins varying significantly between the classes,
the loadings S-plot from the two models were analysed
along with the Variable importance on Projection (VIP)
values (Tables 1 and 2). The loadings S-plots are shown
in Figure 5 (malarial patients and healthy individuals)
and Figure 6 (malarial patients and non malarial fever
patients). The bins accepted for further analysis are
shown in Table 1 (malarial patients and healthy indivi-
duals) and Table 2 (malarial patients and non-malarial
fever patients) along with their loadings and VIP values.
In order to identify the metabolites corresponding to
the spectral bins found significant two-dimensional
NMR techniques such as COSY and TOCSY were
employed, matching of the chemical shifts with values
reported in metabolite databases such as Human
Figure 1 Representative urine
1H NMR spectral profile of I. Adult male patient with non-malarial fever, II. Adult male healthy individual and
III. Adult male infected with Plasmodium vivax. However, due to high variability in the urine profiles of across individuals, a direct comparison of
the spectral profile is not possible. Keys: A: Branched chain amino acid and small chain fatty acids, B: acetate and N-acetyl groups of acetylated
amino acids, C: glucose, carbohydrates and amino acid alpha protons, D: Aromatic amino acids and metabolites, Cit: citrate, Crn: creatine/
phosphocreatine/creatinine and Cre: creatine. The Urea and water regions were excluded from the figure.
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identified are listed in Tables 3 and 4, for the malaria vs
healthy and malaria vs non-malaria fever patients,
respectively.
Integration of spectral peaks and univariate analysis
In order to compare the relative concentrations of the
metabolites identified from OPLS-DA models, the
corresponding
1H NMR spectral peak(s) were integrated.
The results are presented in Figures 7 and 8 for the
malaria patients compared with healthy individuals and
patients with non-malaria fever respectively. Most of the
metabolites showed significant variation across the
classes. For example, the levels of valerylglycine, pipeco-
lic acid, phenylpyruvic acid increased in the urine of
malaria patients (Figure 7A, D, E) while the relative
Figure 3 PCA scores plot showing the variation between urinary metabolic profiles of Plasmodium vivax-infected individuals and non-
malarial fever patients. The PCA scores plot demonstrates that the infection by the parasite brings in considerable variation in the urine profile
of the individuals. Here the variation is seen along PC2. This PCA model was constructed from
1H NMR of 21 patients with P. vivax infection and
12 patients with non-malarial fever. All of the patients were male. Each point represents one sample
1H NMR urine profile. Black square = P.
vivax-infected individuals and red circles = non-malarial fever patients. R
2X for the model = 0.67.
Figure 2 OPLS-DA scores plot showing the variation between urinary metabolic profiles of the Plasmodium vivax-infected patients
and healthy individuals. This model was constructed from
1H NMR data of urine from 21 P. vivax-infected individuals and 21 healthy individuals. The
subjects were all male. Each point in the plot represents one sample
1H NMR spectra. Black square = P. vivax-infected individual and red circle = healthy
individual. The t[1] axis represents the predictive variation among the classes and the to[1] axis represents the variation orthogonal to the class specific
variation. The statistical parameters of the model were as follows- R
2X = 0.41 and Q
2(cum) = 0.67. The ellipse is a 95% Hotelling’sT
2 ellipse.
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decreased in the malaria patients in comparison to that
of healthy individuals (Figure 7G, H, K). Some spectral
resonances had overlap from more than one metabolite
(Figure 7F, I). These signals showed significant variation
across the three groups. Since the contribution of indivi-
dual metabolites towards such signals could not be
ascertained, they are mentioned here collectively.
Several metabolites also showed significant variation
across malaria and non-malarial fever patients. Among
them, glucose and ornithine were increased in the urine
profile of the malaria patients significantly (Figure 8B,
D), while a significant decrease in N-butyrate and acet-
ate levels was observed (Figure 8E, F).
From Figures 7, 8 and Tables 3 and 4, it is evident
that there is little overlap between the sets of metabo-
lites found to be varying across the classes. Therefore
metabolites showing differences between malaria
patients and healthy individuals (Figure 7, Table 3) were
integrated in the spectral profile of non-malarial fever
patients and were compared with the malaria patients
using univariate statistics (Figure 9A-I). Significant
enhancement was observed in the concentration of N-
acetylornithine and tyrosine (Figure 9A, C; p <0 . 0 5f o r
Table 1 OPLS-DA model bins selected for assignment of metabolites based on differences between patients of vivax
malarial and healthy individuals
Increased/Decreased Bin (Chemical
shift)
Loading
values
Variable importance on projection (VIP)
values
Increased in urine metabolic profile of P.vivax infected
patients
2.16 -0.20 3.09
1.40 -0.12 2.11
7.48 -0.11 2.04
3.48 -0.15 2.10
7.44 -0.12 1.79
1.20 -0.09 1.58
Decreased in urine metabolic profile of P.vivax infected
patients
3.04 0.37 5.61
3.68 0.20 2.36
3.80 0.17 2.29
3.00 0.11 1.93
2.04 0.10 1.51
Figure 4 OPLS-DA scores plot showing the variation between urinary metabolic profiles of Plasmodium vivax-infected individuals and
non-malarial fever patients. This model was constructed from
1H NMR data of urine from 21 P. vivax-infected individuals and 12 patients with
non-malarial fever. All of the subjects were male. Each point in the plot represents one sample
1H NMR spectra. Black square = P. vivax-infected
individual and red circle = non-malarial fever patients. The t[1] axis represents the predictive variation among the classes and the to[1] axis
represents the variation orthogonal to the class specific variation. The statistical parameters of the model were as follows- R
2X = 0.67 and Q
2
(cum) = 0.89. The ellipse is a 95% Hotelling’sT
2 ellipse.
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acid showed a trend towards increase in the malaria
patients compared to non-malarial fever, although this
was not statistically significant (Figure 9D, p = 0.08).
Discussion
Plasmodium vivax malaria is more prevalent than P. fal-
ciparum malaria in most parts of India [3]. Infection of
P. vivax is historically believed to be a benign form of
malaria. However recent reports suggest that P. vivax
can also result in several complications including multi-
ple organ failure, acute respiratory distress syndrome
a n dC N Sr e l a t e dp r o b l e m s[ 21-23]. It is, therefore,
becoming even more important to understand the host-
parasite interaction for vivax malaria, specifically how
the host metabolism responds to the parasite infection.
In this paper, a
1H NMR approach is described to
understand this process. Urine metabolic profiles of P.
vivax-infected individuals, healthy individuals, and
patients with non-malarial fever were compared in order
to get the malaria specific signatures.
Metabolic syndromes like lactic acidosis due to
enhanced glycolysis are known complications during
severe malaria [15,24]. However, enhancement in excre-
tion of lactic acid was not observed in vivax-infected
patients. This might be due to low parasitaemia (ranging
from 0.01%-0.1%), resulting in insignificant perturbation
of glucose metabolism. However, a range of other meta-
bolites were found, which differentiate between the
malarial patients and the two control categories.
The urine of malaria patients contained significantly
increased amounts of valerylglycine and phenylpyruvic
acid compared to that of healthy individuals (Figure 7A,
E). However, the level of valerylglycine was not signifi-
cantly different between the malarial patients and non-
malarial fever patients (Figure 9G). Valerylglycine is a
Figure 5 A Representative OPLS-DA loadings S-plot showing relative contribution of bins/spectral variables to clustering of
Plasmodium vivax-infected patients and healthy individuals. This plot corresponds to Figure 2. Each point in the figure represents a bin. The
p(corr)[1] axis represents the correlation of the bin towards the predictive variation shown in Figure 1. The p[1] axis represents the magnitude of
the spectral bins. Bins from region circled in red represents the bins that decreased in the P. vivax infected individuals. Bins from region circled
in black represents the bins that increased in the P. vivax infected individuals. Among them, bins with high p(corr)[1] (< -0.2 for increased and >
0.5 for decreased), high p[1] and VIP above cut-off (listed in Table 1) are selected for further analysis.
Table 2 OPLS-DA model bins selected for assignment of metabolites based on differences between patients of vivax
malarial and non-malarial fevers
Increased/decreased Bin (Chemical shift) Loadings values Variable importance values
Decreased in urine metabolic profile of P.vivax infected patients 2.12 0.28 3.84
1.88 0.23 3.10
7.32 0.21 2.91
Increased in urine metabolic profile of P.vivax infected patients 3.96 -0.24 3.24
3.72 -0.23 3.15
3.76 -0.22 3.02
3.80 -0.20 2.78
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tion of the urinary acylglycines is an indication of
impaired b-oxidation of fatty acid [25]. Therefore, it
may be concluded that the impairment in fatty acid b-
oxidation is associated with febrile condition.
Data presented here also indicates a disturbance in the
phenylalanine metabolism. Phenylalanine is known to be
metabolized by phenylalaninehydroxylase and tetrahydro-
biopterin (THBP) to tyrosine. Alteration of this pathway
leads to the formation of phenylpyruvate. Usually phenyl-
pyruvate is a minor metabolite of phenylalanine. How-
ever, in patients with phenylketonuria, the phenylalanine-
tyrosine pathway is blocked leading to excess formation
of phenylpyruvate [26]. A significantly enhanced excre-
tion of phenylpyruvic acid in the malarial patients com-
pared to healthy individuals was observed in our
experiments (Figure 7E). This ‘phenylketonuric condi-
tion’ is probably arising out of an impaired phenylalanine
metabolism. The data also suggests a possible increase in
the biopterin concentration in the urine of malaria
patients (Figure 7F). Some atypical form of phenylketo-
nuria has been characterized by an increase in the urinary
biopterin, which is caused by malfunction of dihydropter-
idinereductase (DHPR) [26]. Hyperphenylalaninemia is
associated with severe P. falciparum malaria in African
children [27]. However, this does not seem to be the case
i nt h ep r e s e n ts t u d ya st h ep h e n y l p y r u v i ca c i de x c r e t i o n
is not significantly different between the malaria and
non-malarial fever patients (Figure 9E). Although, the
overlapped peaks of phenylalanine and hippurate showed
a significant increase in the urine of malaria patients
compared to that of non-malarial fever patients (Figure
8A), this cannot be taken to an indication of hyperpheny-
lalaninemia. The hyperphenylalaninemic condition may
be an associated complication of fever. However, there
seems to be no study that deals with the metabolite
Table 3 Urinary metabolites perturbed in the Plasmodium vivax-infected patients compared to healthy individuals.
Classes compared Metabolites increased in P. vivax-infected
individuals
Metabolites decreased in P. vivax-infected
individuals
P. vivax-infected individuals and healthy
controls
Valerylglycine Creatine/Phosphocreatine
N - acetylornithine Tyrosine
Salicylurate Glucose
pipecolic acid Guanidoacetate
Phenylpyruvate Alanine
biopterin, 3- hydroxybutyrate N - acetylglutamate
Figure 7 indicates the bin corresponding to each metabolite
Figure 6 A Representative OPLS-DA loadings S- plot showing relative contribution of bins/spectral variables to clustering of
Plasmodium vivax-infected patients and non-malarial fever patients. This plot corresponds to Figure 4. Each point in the figure represents a
bin. The p(corr)[1] axis represents the correlation of the bin towards the predictive variation shown in Figure 1. The p[1] axis represents the
magnitude of the spectral bins. Bins from region circled in red represents the bins that decreased in the P. vivax-infected individuals. Bins from
region circled in black represents the bins that increased in the P. vivax-infected individuals. Among them, bins with high p(corr)[1] [< -0.4 for
decreased and > 0.4 for increased], high p[1] (listed in Table 2) and VIP above cut-off are selected for further analysis.
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interesting aspect to be investigated.
Ornithine is a part of the urea cycle. In the first step
of the cycle, ornithinecarbamoyltransferase (OCT) acts
on ornithine and carbamoylphosphate to begin the nat-
ural detoxification of ammonia. Earlier reports suggested
that elevation of serum value of OCT can be a potential
marker of malaria and this was associated with the
damage of the liver cells in the liver stage of the parasite
[27,28].
Perturbation of OCT levels are likely to result in an
impaired urea cycle. Urea cycle is the major pathway for
ammonia detoxification in mammals. Earlier reports
indicated ammonia toxicity during malaria in mice
model [29]. Observation of significant increase in the
urinary level of both ornithine (Figure 8D) and N-acety-
lornithine (Figure 9A) in malaria patients (compared to
non-malarial fever patients) and an increased level of N-
aceylornithine (compared to healthy individuals) (Figure
7 B )a l s op o i n t st op o s s i b l eh epatic injury and impaired
urea cycle resulting in ammonia toxicity during P. vivax
infection. In the light of results presented here, earlier
reports of statistically significant decrease of ornithine in
the plasma of patients with clinical malaria [27] may be
interpreted as an enhanced excretion of ornithine in
malaria patients.
Pipecolic acid is a minor metabolite of lysine catabo-
lism. In humans, pipecolic acid is found to be associated
with chronic liver disease, pyridoxine dependent epilepsy
and Zellweger syndrome [30-32]. Recent studies in the
murine malaria model show elevated pipecolic acid level
in the urine of NMRI mice [16]. Liver dysfunction is
associated with malaria. However, the cause for the ele-
vated pipecolic acid during malaria remains unclear.
Although statistically not very significant, this metabolite
was present in larger quantities in the urine of malarial
patients compared with non-malarial fever patients (Fig-
ure 9D). Earlier studies showed hyperlysinaemia in the
sera of P. berghei ANKA infected mice [15]. Hyperlysi-
naemia is often related to activation of minor metabolic
pathway hence an enhanced pipecolic acid excretion
[33]. From the data reported here and earlier data from
murine malaria model it seems likely that lysine meta-
bolism is perturbed during the course of malarial infec-
tion. However, the underlying biochemical reason
remains to be addressed.
The non-malarial fever category serves as a control for
general fever related changes that are not specific to P.
vivax infection. Febrile illnesses are often likely to be
misdiagnosed as malaria. Lundqvist and co-workers
showed that borreliosis can be misdiagnosed as malaria
due to the similarity in the symptoms [34]. Poorly exe-
cuted microscopy also sometimes adds on to this, lead-
ing to malaria overdiagnosis and overuse of anti-
malarial in malaria endemic regions [35,36]. In this
report, it is shown that the non-malarial fevers can be
separated from vivax patients on the basis of the urinary
metabolite profile of the patients. The urine metabolo-
m i cp r o f i l es e e m st ob es i g n i f i c a n t l yd i f f e r e n ti nt h e s e
two categories (Figures 3 and 4). This is due to the dif-
ference in the levels of Phenylalanine, hippurate, glu-
c o s e ,g l u t a m i n e ,a l a n i n e ,a n do r n i t h i n ew h i c ha r e
increased in the urine of the P. vivax-infected indivi-
duals and n-butyrate and acetate which are decreased in
these patients (Figure 8, Table 4). Pipecolic acid also
showed a higher trend in the urine of malaria patients
compared to non-malarial fever patients (Figure 9D). As
is evident from a very high Q
2(cum) which is equal to
0.89 from the OPLS-DA model made from the urinary
metabolite profile of the non-malarial fever patients and
P. vivax-infected individuals, urinary metabolic profiles
have a potential to be of diagnostic use for detecting
malaria and to differentiate malaria from other non-
malarial fevers.
Conclusions
This study reports on the understanding of the host
metabolic changes in terms of the urinary metabolite
profile of the P. vivax-infected patients. Urinary metabo-
lite profile of malaria patients were found to be distinct
from both healthy individuals and those of non-malarial
fever patients. Among several changes in metabolism, a
Table 4 Urinary metabolites perturbed in the Plasmodium vivax-infected patients compared to non-malarial fever
patients.
Classes compared Metabolites increased in P. vivax-infected
individuals
Metabolites decreased in P. vivax-infected
individuals
P. vivax-infected individuals and patients with non-
malarial fever
L-phenylalanine N-butyrate
Hippurate Acetate
Glucose
Glutamine
Alanine
Ornithine
Figure 8 indicates the bin corresponding to each metabolite
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Page 9 of 13disruption in the urea cycle in terms of ornithine excre-
tion was noted, along with an elevated level of pipecolic
acid indicating possible hepatic injury. Ornithine, there-
fore, promises to be candidate biomarker for malarial
infection. Moreover, an extremely predictive model was
constructed from urinary metabolite profile of the
clinical malaria patients and individuals with non-malar-
ial fever. This might help in the non-invasive diagnosis
of malarial infection. Malaria-specific signatures were
observed in the urine and showed that the urine profile
of malaria patients cluster separately from different
groups of control populations in spite of the high
Figure 7 The level of perturbed metabolites in the urine of Plasmodium vivax-infected and healthy individuals. All peak intensities were
calculated in terms of actual integrated value of individual NMR spectral peak normalized to the total spectral intensity. Panels with more than
one metabolite represent an overlap in the peak of metabolites in the spectrum. Red = P. vivax-infected individuals and black = healthy
individuals. + indicates p < 0.05.
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Page 10 of 13Figure 8 The level of perturbed metabolites in the urine of Plasmodium vivax-infected and non-malarial fever patients.A l lp e a k
intensities were calculated in terms of actual integrated value of individual NMR spectral peak normalized to the total spectral intensity. Panels
with more than one metabolite represent an overlap in the peak of metabolites in the spectrum. Red = P. vivax-infected individuals and gray =
non-malarial fever patient. + indicates p < 0.05.
Figure 9 The level of perturbed metabolites in the urine of Plasmodium vivax-infected and non-malarial fever patients. Only those
peaks are integrated which showed no overlap in the spectra and showed significant variation across the P. vivax-infected patients and healthy
individuals. All peak intensities were calculated in terms of actual integrated value of individual NMR spectral peak normalized to the total
spectral intensity. Red = P. vivax-infected individuals and grey = non-malarial fever patient. + indicates p < 0.05.
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Page 11 of 13variability of urine metabolites across individuals. This
study, therefore opens up the possibility of finding out
malaria specific biomarkers in the urine, which might
help in non invasive diagnosis of the infection in the
long run. Many parameters, such as genetic make up,
food habits and lifestyle, may influence urine metabolite
patterns. In order to circumvent such confounding para-
meters, a longitudinal follow up and comparison of
urine from cohorts of malaria patients and other control
subjects will provide further specific information regard-
ing disease related changes in patients of P. vivax
malaria.
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